AstraZeneca (AZN.L) said Monday its ceralasertib-Imfinzi combination failed to improve survival in advanced lung cancer patients, sending shares down 1% as investors weighed the setback against the drugmaker’s broader oncology pipeline. The trial failure represents a significant blow to AstraZeneca’s...